Xoma | Date: 2016-08-05
The present disclosure relates, in general, to methods of treating or preventing hypoglycemia using a negative modulator antibody fragment that binds to the insulin receptor and modulates the action of insulin at the insulin receptor.
Xoma | Date: 2016-11-11
A flexible, multi-product, multi-technology, expandable facility for manufacturing products, such as biologicals, pharmaceuticals, or chemicals, and manufacturing processes using elements of such a facility.
Xoma | Date: 2017-02-01
Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1 antibody or fragment thereof.
Novartis and Xoma | Date: 2016-11-09
M-CSF-specific RX1-based or RX-1 derived antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating bone loss in a subject afflicted with an osteolytic disease.
Xoma | Date: 2017-07-05
The present invention provides polypeptide binding agents, e.g. antibodies, that exhibit the ability to kinetically modulate the binding and signaling of biological signaling complexes, e.g., receptor-ligand complexes; methods of identifying such polypeptide binding agents, methods of making such polypeptide binding agents, compositions comprising such polypeptide binding agents, and methods of using such polypeptide binding agents.
Xoma and Novartis | Date: 2016-05-11
PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
Xoma and The Regents Of The University Of California | Date: 2016-04-03
The present disclosure relates, in general, to combination therapy using an inhibitor of transforming growth factor beta (TGF) and an inhibitor of programmed cell death protein 1 (PD-1) for treating cancer or preventing recurrence of cancer diseases such as lung cancer, prostate cancer, breast cancer, hepatocellular cancer, esophageal cancer, colorectal cancer, pancreatic cancer, bladder cancer, kidney cancer, ovarian cancer, stomach cancer, fibrotic cancer, glioma and melanoma, and metastases thereof.
Xoma | Date: 2016-08-03
The present disclosure relates to methods and materials for treating acne in a subject including, for example, moderate and/or severe acne, using anti-IL-1 binding molecules such as an anti-IL-1 antibody or binding fragment thereof.
Xoma | Date: 2016-08-17
An IL-1 binding antibody or IL-1 binding fragment thereof comprising a light chain variable region comprising the amino acid sequence of SEQ ID NO: 11 and a heavy chain region comprising the amino acid sequence of SEQ ID NO:15, and related nucleic acids, vectors, cells, and compositions.
Xoma | Date: 2016-02-03
The present disclosure relates to methods and materials for mutagenesis, including for the generation of novel or improved proteins and libraries or arrays of mutant proteins or nucleic acids encoding such mutant proteins.